GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Portal Therapeutics, Inc.
Study ID
NCT06971900
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Erythropoietic Protoporphyria (EPP)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • PORT-77 — DRUG
    Active oral dose form
  • Placebo — DRUG
    Matching inactive oral dose form

Study Details

A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)

Key Dates

Start date
Apr 4, 2025
Status verified
Apr 2025
Primary completion
Jan 1, 2026
Completion
Jan 31, 2026

Study Design

Enrollment
14 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: PORT-77
    Active
  • Placebo Comparator: Placebo
    Placebo

Primary Outcome Measure

Plasma PPIX level [ Time Frame: 9 Days ]

Locations (1)

FacilityCityStateZIPSite coordinators
CelerionTempeArizona85283-

Find similar trials in Tempe, AZ

By research site
Celerion· Tempe, AZ

Related Studies